42 results about "Furoxan" patented technology

The invention describes compositions and kits comprising at least one organic nitric oxide enhancing salt of an angiotensin π antagonist, and, optionally, at least one nitric oxide enhancing compound and/or at least one therapeutic agent. The invention also provides methods for (a) treating cardiovascular diseases; (b) treating renovascular diseases; (c) treating diabetes; (d) treating diseases resulting from oxidative stress; (e) treating endothelial dysfunctions; (f) treating diseases caused by endothelial dysfunctions; (g) treating cirrhosis; (h) treating pre-eclampsia; (j) treating osteoporosis; (k) treating nephropathy; (l) treating peripheral vascular diseases; (m) treating portal hypertension; (n) treating ophthalmic disorders; (o) treating metabolic syndrome; and (p) treating hyperlipidemia. The organic nitric oxide enhancing compounds that form salts with the angiotensin II antagonists are organic nitrates, organic nitrites, nitrosothiols, thionitrites, thionitrates, NONOates, heterocyclic nitric oxide donors and/or nitroxides. The heterocyclic nitric oxide donors are furoxans, sydnonimines, oxatriazole-5-ones and/or oxatriazole-5-imines.

The invention discloses a 3,4-di(3',5'-dinitryl-4'-methyl phenyl) furoxan compound, the structural formula of which is shown in the specification. The compound is mainly applied to energetic materials.

The invention discloses a preparation method of high-energy explosive 3,4-di(nitrofurazano)furoxan. Raw material 3-amino-4-acyl chloride oximidofurazan reacts with weak base solid silver carbonate in solvents such as tetrahydrofuran to generate an intermediate 3,4-di(amino furazano)furoxan with the yield of 80%. The preparation method disclosed by the invention overcomes the defects in the prior art, and no BAFF (B Cell Activating Factor) isomer 3,6-bi(3-amino furazan-4-base)-1,4-dioxa-2,5-diazacyclohexane-2,5-diene is generated; then, the BAFF is oxidized by using a mixture of hydrogen peroxide and concentrated sulfuric acid as an oxidant to generate the high-energy explosive BNFF, and the yield can reach 80%. The preparation method of the high-energy explosive BNFF is high in production efficiency, low in material cost, mature, stable, safe and reliable, and has engineering application prospect.

The invention discloses a synthesis method of 3,4-bi(4'-nitrophenyl) oxidized furoxan. The structure formula thereof is shown as (I), and the synthesis method adopts p-nitrobenzaldehyde as raw material; the structure formula thereof is shown as (II), and the synthesis method comprises the following steps: 1) adding the p-nitrobenzaldehyde and alcohol into a reaction flask, then adding hydroxylamine hydrochloride aqueous solution, using Na2CO3 aqueous solution to adjust pH of reaction liquid to 6 to 8, reacting for 1 to 2 hours at the temperature of 10 to 40 DEG C, obtaining p-nitrobenzaldoxime, with the molar ratio of the p-nitrobenzaldehyde and hydroxylamine hydrochloride of 1:1 to 1:1.5; and 2) adding the p-nitrobenzaldoxime, chlorosuccinimide and trichloromethane into the reaction flask, with the molar ratio of the p-nitrobenzaldoxime and chlorosuccinimide of 1:1 to 1:1.5, reacting for 1 to 3 hours at the temperature of 20 to 40 DEG C, using Na2CO3 solution to adjust pH of a system to 6 to 8 at the temperature of 0 to 5 DEG C, reacting for 1 to 4 hours and obtaining the objective product, namely the 3,4-bi(4'-nitrophenyl) oxidized furoxan. The synthesis method is mainly used for the 3,4-bi(4'-nitrophenyl) oxidized furoxan.

The invention describes compositions and kits comprising at least one cardiovascular compound comprising at least one heterocyclic nitric oxide donor group, and, optionally, at least one nitric oxide enhancing compound and/or at least one therapeutic agent. The invention also provides methods for (a) treating cardiovascular diseases; (b) treating renovascular diseases; (c) treating diabetes; (d) treating diseases resulting from oxidative stress; (e) treating endothelial dysfunctions; (f) treating diseases caused by endothelial dysfunctions; (g) treating cirrhosis; (h) treating pre-eclampsia; (j) treating osteoporosis; (k) treating nephropathy; (l) treating peripheral vascular diseases; (m) treating portal hypertension and (n) treating ophthalmic disorders. The cardiovascular compounds are preferably β-adrenergic antagonists, angiotensin-converting enzyme (ACE) inhibitors, anti-hyperlipidemic compounds, and antithrombotic and vasodilator compounds. The heterocyclic nitric oxide donor groups are preferably furoxans, sydnonimines, oxatriazole-5-ones and/or oxatriazole-5-imines.

The invention relates to a furoxan ring, and provides a synthesis method of 3, 4-dicarboxylic acid diethyl ester furoxan. The method adopts a monoethyl malonate potassium salt as a raw material and takes sodium nitrate/nitrite as an oxidizing agent. The substances are subjected to oxidation nitration and a ring formation reaction in a carbon tetrachloride solution, thus obtaining the target compound 3, 4-dicarboxylic acid diethyl ester furoxan with purity up to 98.7% and yield up to 94.2%. The synthesis method provided in the invention has the advantages of high purity and high yield.

The invention discloses a furoxan NO donor-type statin derivative and a preparation method thereof, and belongs to the technical field of medicinal chemical synthesis. The derivative has the structural formula represented by the following formula: wherein R is an alkyl, R1 is a statin residual group, and R2 is an aryl or an aryl sulfonyl. A statin drug is selected to "hybridize" with a NO donor, both NO and the statin drug have good therapeutic effects on atherosclerosis, and the problem of the mismatch of action mechanisms of NO and the statin drug is effectively avoided. In addition, 4-coumaric acid is selected as a linking group, and thus the therapeutic effect of the drug can be effectively enhanced. The compound can effectively release NO in vitro, and the useful attempt for the development of NO donor anti-atherosclerosis drugs is made.

The invention provides a synthetic method for 3-(4-aminofurazan-3-radical)-4-(4-nitrofurazan-3-radical) furazan. 3-(4-aminofurazan-3-radical)-4-(4-nitrofurazan-3-radical) furazan (ANTF) is a low-melting-point (100 DEG C) explosive, is expected to replace TNT to be used in casting explosives, and is also an intermediate for synthesizing other novel explosives. An existing synthetic method of ANTF has the defects of being large in acid use amount, low in synthesis yield, strict in reaction condition and the like. 3,4-bis(3'-aminofurazan-4'-radical) furoxan (BAFF) is adopted as a raw material, 3,4-bis(3'-aminofurazan-4'-radical) furoxan (BAFF) and SnCl2.2H2O are firstly subjected to a reduction reaction to obtain 3,4-bis(aminofurazan-4-raidcal) furazan, and then 3,4-bis(aminofurazan-4-raidcal) furazan and H2O2 are subjected to an oxidizing reaction to obtain the target product 3-(4-aminofurazan-3-radical)-4-(4-nitrofurazan-3-radical) furazan. 3,4-bis(aminofurazan-4-raidcal) furazan is adopted as the raw material, H2O2 (20%-30%) is adopted as an oxidizing agent, Na2WO4 is adopted as a catalyst, and 3-(4-aminofurazan-3-radical)-4-(4-nitrofurazan-3-radical) furazan is synthesized under the acidic condition through the oxidizing reaction. The synthetic method has the advantages of being easy and convenient to operate, high in safety, controllable in process and the like.

The invention provides novel furoxan compounds, or pharmaceutically acceptable salts thereof, and novel compositions comprising at least one compound, and, optionally, at least one nitric oxide enhancing compound and/or at least one therapeutic agent. The compounds and compositions of the invention can also be bound to a matrix. The invention also provides methods for (a) treating cardiovascular diseases; (b) inhibiting platelet aggregation and platelet adhesion caused by the exposure of blood to a medical device; (c) treating pathological conditions resulting from abnormal cell proliferation; (d) treating transplantation rejections, (e) treating autoimmune, inflammatory, proliferative, hyperproliferative or vascular diseases; (f) reducing scar tissue or for inhibiting wound contraction; (g) treating diseases resulting from oxidative stress; (h) treating endothelial dysfunctions; and (j) treating diseases caused by endothelial dysfunctions.

The invention discloses a synthesis method of a furazan oxide compound. The synthesis method comprises the following step of: oxidizing a glyoxime compound by taking iodobenzene diethyl ester as an oxidizing agent to carry out a reaction to obtain the furazan oxide compound. No heavy metal, acid or alkali participates in the reaction process. The method has the advantages of mild reaction conditions, high efficiency, green and environment-friendly process, simple post-treatment and the like, and is a synthetic method with a certain industrial value; besides, the reaction raw materials do not contain acyl chloride compounds with higher activity, no strict requirements are imposed on substituent groups of the furoxan compound, so that a new synthesis path is opened up for the furoxan compound containing groups which are easy to react with the acyl chloride compounds.

The invention discloses a method for directly synthesizing furoxan from methyl ketone, and belongs to the technical field of organic chemical synthesis. According to the method, methyl ketone is usedas a raw material, methyl ketone and a green nitration reagent tert-butyl nitrite (TBN) are subjected to a free radical reaction in an air or oxygen atmosphere with acetonitrile, toluene or 1, 4-dioxane as a reaction solvent to directly synthesize the furoxan. According to the method, a metal catalyst is not used in the synthesis process, acid and alkali are avoided, tert-butyl nitrite directly participates in the reaction, the tert-butyl nitrite is low in price and good in functional group compatibility, and the nitration reagent is very green. The methyl ketone can be directly purchased commercially, so that the reaction path is shortened and the workload of raw material preparation is saved compared with the traditional synthesis method. And meanwhile, the method only generates the target product furoxan, so that the environmental pollution and the difficulty of product post-treatment are reduced.